PROTECT: Prospective Trial on Erythropoietin in Clinical Transplantation
Launched by LEIDEN UNIVERSITY MEDICAL CENTER · Sep 7, 2005
Trial Information
Current as of June 06, 2025
Completed
Keywords
ClinConnect Summary
Randomized, double blind, placebo controlled, prospective trial in patients, receiving a kidney transplantation. Patients will be randomized to receive either Epoetin Beta (Neorecormon; Roche) or placebo.
The primary endpoint will be delayed graft function. The anticipated duration of this trial is 2 year and the target sample size is 60 patients per arm.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult patients
- • Receiving a kidney from a non-heart-beating donor category 3
- Exclusion Criteria:
- • Donor related factors: a prolonged warm ischaemic time (\> 45 min); a cold ischaemic time of \> 24 hours; serum creatinin of \> 150 umol/l
About Leiden University Medical Center
Leiden University Medical Center (LUMC) is a prominent academic medical center located in the Netherlands, renowned for its commitment to advancing healthcare through innovative research and high-quality patient care. As a clinical trial sponsor, LUMC focuses on translating scientific discoveries into effective therapies, fostering collaborations between researchers, clinicians, and industry partners. The center is dedicated to conducting rigorous clinical studies across various medical fields, ensuring adherence to ethical standards and regulatory requirements while prioritizing patient safety and outcomes. Through its multidisciplinary approach, LUMC aims to contribute significantly to the understanding and treatment of complex health conditions, driving progress in personalized medicine and improving global health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Leiden, , Netherlands
To Be Determined, , Netherlands
Patients applied
Trial Officials
Ton Rabelink, MD, PhD
Study Chair
Leiden University Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials